Catalog

GLP-1 receptor agonist

The molecule that rewrote what weight loss looks like.

A long-acting GLP-1 analog that turns down appetite and slows gastric emptying. It is FDA-approved for type 2 diabetes and chronic weight management, and it carries some of the largest randomized outcome data of any peptide in this catalog.

2 of 2 claims human-tested · 4 references · FDA-approved

GIP / GLP-1 dual receptor agonist

Two incretin receptors, one injection, up to ~21% body weight gone.

A once-weekly dual agonist that hits both the GIP and GLP-1 receptors. In its pivotal obesity trial it drove weight loss rivaling bariatric surgery, and it is FDA-approved for type 2 diabetes, obesity, and obstructive sleep apnea.

1 of 1 claims human-tested · 3 references · FDA-approved

Growth-hormone fragment

The 'fat-burning fragment' the clinic couldn't confirm.

A synthetic fragment of human growth hormone marketed for lipolysis. It showed fat-metabolism activity in preclinical work, but company-run human weight-loss trials failed to beat placebo — a clean example of a great story meeting hard endpoints.

1 of 2 claims human-tested · 2 references · Research-only

Mitochondrial-derived peptide

An 'exercise mimetic' written into your mitochondrial DNA.

A 16-amino-acid peptide encoded within mitochondrial DNA that activates AMPK and improves insulin sensitivity — the closest thing to a molecular echo of exercise. The mechanism work is elegant and Western peer-reviewed; human data is early and mostly associative.

1 of 2 claims human-tested · 2 references · Research-only

GIP / GLP-1 / glucagon triple agonist

The triple agonist posting the biggest weight-loss numbers yet.

An investigational once-weekly peptide that activates three metabolic receptors at once. Phase 2 data are striking, but it is not yet approved — this is late-stage clinical promise, not a settled therapy.

1 of 2 claims human-tested · 3 references · Research-only